Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
07 Enero 2024 - 7:00AM
Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology
Company®, today announced that it has entered into a license and
distribution agreement with Thermo Fisher Scientific, Inc. The
agreement enables Akoya to market the combination of Akoya’s
spatial biology solutions, including its PhenoImager® systems and
PhenoCode™ reagents with the Thermo Fisher ViewRNA In Situ
Hybridization Assays, for detection of protein and RNA biomarkers
in tissue samples.
The agreement facilitates a streamlined workflow for
whole-slide, multiomic imaging, where protein and RNA biomarkers
play complementary roles in defining cell phenotypes and cell
states, respectively, in a tissue sample. Measuring both protein
and RNA analytes provides researchers with a more comprehensive
understanding of tumor progression, molecules and biologics,
enabling development of more accurate biomarker signatures.
The Thermo Fisher ViewRNA assays are compatible with Akoya's
PhenoCode™ protein panels, which deliver industry-leading solutions
for high-plex and high-throughput spatial proteomics. The aim is to
offer a comprehensive suite of ready-to-use and customizable
multiomic solutions, streamlining the progression of biomarker
programs from discovery to diagnostics.
“We are excited to work with Thermo Fisher to combine their RNA
solutions with our platforms to offer a leading multiomic solution
for researchers to further advance the spatial biology field,” said
Brian McKelligon, CEO, Akoya Biosciences.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
expectations about the potential of our products and services and
other matters regarding our business strategies and plans and
objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
To learn more about Akoya, visit www.akoyabio.com.
Akoya Biosciences Investor Contact:
Priyam ShahSr. Director, Investor
Relationsinvestors@akoyabio.com
Akoya Biosciences Media Contact:
Christine Quernmedia@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Akoya BioSciences (NASDAQ:AKYA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024